Abstract
Tibolone is a synthetic compound, which binds to estrogen, progesterone, and androgen receptors. Previous studies have shown favorable effects on bone, the vagina, the cardiovascular system, climacteric symptoms, mood, and libido without detrimental estrogen-like stimulation of the breast and endometrium [1 – 4]. Studies have indicated that tibolone increases bone mineral density (BMD) relative to baseline or placebo over periods ranging from 6 months to 3 years [3]. Two large, multicenter, randomized, double-blind, placebo-controlled, dose-finding studies were performed in North America. These studies were intended to evaluate the efficacy of different doses of tibolone in the prevention of bone loss in early postmenopausal women, and to determine the minimum effective dose of tibolone.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kloosterboer HJ. Tibolone and its metabolites: Pharmacology, tissue specificity and effects in animal models of tumors. Gynecol Endocrinol 2001; 11(Suppl.l):63–68.
Kloosterboer HJ, Sands R. Intracrinology: The secret of the tissue-specificity of tibolone. Journal of British Menopause Society 2000; Supplement S2:23–27.
Moore RA. Livial: A review of clinical studies. Br J Obstet Gynaecol 1999; 106(Suppl. 19): 1–21.
Tang B, Markiewicz L, Kloosterboer HJ, Gurpide E. Human endometrial 3 beta-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/ progestagen activity ratios of a steroidal drug (Org OD 14). J Steroid Biochem Molec Biol 1993;45(5):345–51.
Ederveen AG, Kloosterboer HJ. Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. J Bone Miner Res 2001; 16:in press.
Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348:1535–41.
Ravn, P., Bidstrup, M., Wasnich, R.D., et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999; 131(12); 935–42.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gallagher, J.C. (2002). Tibolone Is Effective in Preventing Postmenopausal Bone Loss. In: Lobo, R.A., Crosignani, P.G., Paoletti, R., Bruschi, F. (eds) Women’s Health and Menopause. Medical Science Symposia Series, vol 17. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1061-1_8
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1061-1_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5375-1
Online ISBN: 978-1-4615-1061-1
eBook Packages: Springer Book Archive